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Objectives: The importance of treating the bilateral neck in lateralized small oral cavity squamous cell carcinoma
(OCC) is unclear. We sought to define the incidence and predictors of contralateral neck failure (CLF) in patients
who underwent unilateral treatment.
Materials and methods: We performed a multi-institutional retrospective study of patients with pathologic T1-T2
(AJCC 7th edition) OCC with clinically node negative contralateral neck who underwent unilateral treatment
with primary surgical resection ± adjuvant radiotherapy between 2005 and 2015. Incidence of CLF was esti
mated using the cumulative incidence method. Clinicopathological factors were analyzed by univariate (UVA)
and multivariate analysis (MVA) for possible association with CLF. Kaplan-Meier analysis was used to estimate
overall survival (OS).
Results: 176 patients were evaluated with a median of 65.9 months of follow-up. Predominant pathologic T-stage
was T1 (68%), 8.5% of patients were N1, 2.8% were N2b. Adjuvant radiotherapy was delivered to 17% of pa
tients. 5-year incidence of CLF was 4.3% (95% CI 1.2–7.4%). Depth of invasion (DOI) > 10 mm and positive
ipsilateral neck node were significant predictors for CLF on UVA. DOI > 10 mm remained significant on MVA
(HR = 6.7, 95% CI 1.4–32.3, p = 0.02). The 2- and 5-year OS was 90.6% (95% CI 86.2–95.0%) and 80.6% (95%
CI 74.5–86.8%), respectively.
Conclusion: Observation of the clinically node negative contralateral neck in small lateralized OCC can be a
suitable management approach in well selected patients, however caution should be applied when DOI upstages
small but deeply invasive tumors to T3 on 8th edition AJCC staging.

Introduction
Oral cavity cancers (OCC) associated with a high incidence of
contralateral neck metastases include advanced T-stage tumors or tu
mors that abut or cross midline [1]. Elective neck dissection (END) to the
clinically node negative (cN0) contralateral neck, as part of primary

surgical management, may be offered for these primary tumors. In the
absence of an END, radiotherapy (RT) to the contralateral neck should
be delivered as a method of managing potential microscopic disease [2].
Recommended management of the cN0 contralateral neck in later
alized small, early T-stage OCC is less clear [2,3]. Contralateral neck
management with END or RT in these tumors may add unnecessary
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competing event. Significant clinico-pathological predictors on UVA
were included in multivariate analysis (MVA). OS of the cohort was
estimated with the Kaplan-Meier method. Pathological staging was
based on 7th edition AJCC system as this was recorded in the multiinstitutional collaborative database. The cumulative incidence, hazard
ratios and OS were reported with 95% confidence intervals (CI) and
statistical significance was determined with p-value < 0.05. Statistical
analysis was performed using SAS v9.4(SAS Institute, Cary, NC).

morbidity without significant gains in tumor control or survival [4,5].
The lymphatic drainage pattern of predominantly lateralized (89%) T1/
T2N0 OCC was demonstrated in the SENT trial [6]. The rate of drainage
to the contralateral neck was 12% of cases [6]. However, of 415 patients
in the SENT trial, only 7 patients (2%) had a clinically occult contra
lateral neck nodal metastases [6]. Pathological studies of END speci
mens from T1/T2 oral tongue squamous cell carcinoma (SCC) that did
not cross midline also showed the rate of clinically occult contralateral
neck nodal metastases to be < 5% [7–9]. Furthermore, studies that
evaluated unilateral treatment outcomes for lateralized OCC have
shown low rates of contralateral neck failure of < 10% [10–13]. Thus,
treating the cN0 contralateral neck in these primary tumors is not
routinely recommended [2,14].
However, practice variation exists in terms of managing the cN0
contralateral neck in lateralized small, early T-stage OCC as there is no
high level evidence from randomized controlled trials (RCT) to recom
mend a standard of care [12,15]. Proponents of comprehensive neck
management in OCC that recommend END and/or RT to the cN0
contralateral neck, provide the rationale that OCC, in particular oral
tongue primary cancers, have rich lymphatic channels, that aberrant
lymphatic drainage following ipsilateral neck dissection may occur to
the contralateral neck following primary surgical management and
successful salvage rates of regional recurrences are low [16–18].
We conducted a multi-institutional retrospective study of patients
with OCC treated with primary surgical management to evaluate out
comes and assess for potential prognostic factors. As the importance of
treating the bilateral neck in lateralized small OCC is unclear, the pur
pose of this study was to analyze the incidence of contralateral neck
failure (CLF) and clinico-pathological predictors for CLF in these tumors
treated unilaterally.

Results
Study cohort
Of 1282 patients in the multi-institutional database, 176 patients met
inclusion criteria and were included in this study. The median follow-up
was 65.9 months (range, 1–157). Median age was 59 years old (range,
22–93) and 60% were male. The most common primary site was oral
tongue (82%).
The predominant pathological T-classification was T1 (68%). The
majority of patients had node negative disease in the ipsilateral neck
(pN0 – 81%). Adjuvant RT to the primary and/or ipsilateral neck was
delivered in 17% of patients. Additional details of the study cohort are
Table 1
Study population.
Patient number
Median age in years (range)
Gender
Male (%)
Female (%)
Tobacco/Betel Use
Yes
No
Alcohol Use
Yes
No
Unknown
Tumor site
Oral tongue (%)
Floor of mouth (%)
Pathological T-classification (7th edition AJCC)
T1 (%)
T2 (%)
Depth of invasion
≥4mm
<4mm
>10 mm
≤10 mm
Unknown
Tumor differentiation
Well
Moderate
Poor
Unknown
Lymphovascular space invasion
Present
Absent
Unknown
Perineural invasion
Present
Absent
Unknown
Ipsilateral neck involvement
Pathological N0 (%)
Pathological N+ (%)
– N1*
– N2b*
– Unknown N-classification*
Unknown
Ipsilateral RT
Yes
No

Methods and materials
Study population
This retrospective study was part of the Multi-institutional Oral
Cavity Cancer Collaborative (MOCCC) effort to evaluate the outcomes of
OCC treated definitively with surgery between January 2005 and
January 2015. We evaluated outcomes of patients from five academic
institutions with pathologic stage T1-2 (7th edition American Joint
Committee of Cancer [AJCC]) OCC, treated with surgery ± ipsilateral
neck treatment (neck dissection and/or RT). Patients were excluded if
they had disease in the contralateral neck, underwent treatment to the
contralateral neck (bilateral neck dissection/RT, adjuvant chemo
therapy), unknown side of neck dissection/RT, or had high risk features
(positive surgical margin or extranodal extension) that would typically
warrant comprehensive neck treatment. We defined these inclusion and
exclusion criteria to best represent patients who were thought to have
small lateralized OCC at the time of treatment and were assessed to only
require unilateral treatment.
This study was approved by Institutional Review Board/Human
Research Ethics Committee at each respective institution.
Statistical analyses
The primary endpoint of this study was to assess the incidence of CLF
as first site of regional disease recurrence. Secondary endpoints were to
assess clinico-pathological predictors for CLF and to evaluate overall
survival (OS) for the cohort.
The 2- and 5-year incidence of CLF was estimated using the cumu
lative incidence method, with ipsilateral neck failure as a competing
event. Synchronous bilateral neck failure was considered a CLF. Local
failure/s occurring prior to regional failure were not considered a
competing or censored event. Univariate analysis (UVA) was performed
to assess clinico-pathological predictors of CLF using Fine-Gray
competing risk regression analysis, with ipsilateral neck failure as a

176
59 (22–93)
106 (60%)
70 (40%)
127 (72%)
49 (28%)
128 (73%)
44 (25%)
4 (2%)
145 (82%)
31 (18%)
119 (68%)
57 (32%)
39 (22%)
84 (48%)
19 (11%)
104 (59%)
53 (30%)
48 (27%)
100 (57%)
22 (13%)
6 (3%)
13 (7%)
154 (88%)
9 (5%)
30 (17%)
137 (78%)
9 (5%)
143 (81%)
21 (12%)
15 (8%)
5 (3%)
1 (1%)
12 (7%)
30 (17%)
146 (83%)

* N-classification was based on 7th edition AJCC staging.
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In T1/T2 cN0 OCC lateralized to one side of midline, RCT data
supports the use of ipsilateral END due to improved OS and disease free
survival compared to therapeutic neck dissection at the time of nodal
relapse [19]. However, there is no RCT data to guide standard of care
management of the contralateral cN0 neck in this subgroup. Whilst the
RCT performed by D’Cruz et al. demonstrated a survival benefit with
ipsilateral END in early stage OCC, it is unclear what the role of
contralateral END is in this setting [19]. There was an 11.9% nodal
recurrence rate in the END group (N = 29/243), although the side
(ipsilateral vs. contralateral) of neck recurrence was not reported [19].
Furthermore, adjuvant RT to the neck was delivered in 28.4% of patients
in the END group with parallel opposed fields, so the contralateral neck
is presumed to have received some dose.
The treatment of the cN0 neck in head and neck SCC is typically
recommended when the risk of occult metastases is >20% [20]. For the
cN0 contralateral neck, expert guidelines suggest that there is substan
tial risk of occult metastases in oral tongue/floor of mouth tumors that
are T3/T4 (8th edition AJCC) or approach midline and thus the bilateral
neck should be treated comprehensively either with END or RT [2]. In
lateralized small, early T-stage OCC however, the role of treating the
neck comprehensively with inclusion of the contralateral cN0 neck is
less clear. Our data suggests that omitting treatment to the contralateral
cN0 neck in this subgroup is acceptable given the low 5-year incidence
of CLF of 4.3%. Furthermore, upon CLF, 7 of 9 patients underwent
salvage neck dissection (78%). It is important to note however, that the
cohort presented here were well selected patients that predominantly
had T1 (68%) and node negative (81%) disease. The cohort was
considered low risk to warrant RT in 17% of cases, and was associated
with favourable prognosis as demonstrated by the high OS rates.
Nonetheless, regional recurrences can have detrimental impact on OCC
prognosis [3]. Thus, considerable thought in the setting of a multidis
ciplinary tumor board should be performed for both patient selection
and minimizing unnecessary morbidity when managing the contralat
eral cN0 neck. Our results are consistent with published reports of CLF
< 10% as detailed in Table 4, and is likely a reflection of well selected
patient cohorts as the studies listed were all retrospective in nature. The
SENT trial however, provides prospective data of the low risk of clini
cally occult metastases in the contralateral neck. In this prospective
observational trial of early T-stage, cN0 OCC evaluating the role of
sentinel node biopsy, 369 patients had lateralized tumors [6]. Of these
lateral tumors, the drainage pattern was 10.8% to the bilateral neck and
2.4% exclusively to the contralateral neck. However, a positive contra
lateral sentinel node was only detected in 1.9% of cases (N = 7/369). For
early T-stage OCC including midline tumors that did present with occult
metastases, the contralateral neck was involved in 6% of cases (N = 7/
109) [6]. Thus, watchful waiting can be a reasonable management
approach to the contralateral cN0 neck in small lateralized OCC.
The challenge of clinical decision making in managing the

summarized in Table 1.
Regional failure rate
Regional failure was seen in 32 patients (18%). Ipsilateral neck
failure occurred in 23 patients (13%) and 9 patients had CLF (5%). Of
these 9 patients, 2 had synchronous bilateral neck failure (1%). Of the
patients who had CLF, the pathological features, any local failure and
treatment for CLF are summarized in Table 2. Four patients with CLF
had experienced a local failure; two local failures occurred prior to CLF
and two local failures were synchronous with CLF. The number of pa
tients with any local, loco-regional, or regional disease failure are
summarized in Supplementary Table 1.The estimated cumulative inci
dence of CLF at 2 years was 3.6% (95% CI 0.8–6.5%) and at 5 years was
4.3% (95% CI 1.2–7.4%) (Fig. 1). The estimated cumulative incidence of
ipsilateral neck failure at 2 years was 11.9% (95% CI 7.0–16.8%) and at
5 years, was 13.3% (95% CI 8.1–18.5%).
Clinico-pathological predictors of contralateral neck failure
On UVA, pathological predictors for CLF was depth of invasion
(DOI) > 10 mm and ipsilateral neck node positive status (Table 3). There
were no significant clinical predictors of CLF. On MVA, DOI > 10 mm
remained a statistically significant predictor for CLF (p = 0.02) with an
adjusted hazard ratio of 6.7 (95% CI 1.4–32.3) for risk of CLF compared
to tumors with DOI ≤ 10 mm.
Overall survival
The estimated 2- and 5- year OS for the entire cohort was 90.6%
(95% CI 86.2–95.0%) and 80.6% (95% CI 74.5–86.8%), respectively
(Fig. 2). For patients who had no regional failure, the estimated 5-year
OS was 85.1% (95% CI 78.9–91.3%) (Fig. 3). For patients who had a
regional failure, the estimated 5-year OS for ipsilateral neck failure was
63.8% (95% CI 43.7–83.9%), and for CLF was 55.5% (23.1–88%),
respectively.
Discussion
This multi-institutional study represents the largest series to report
the incidence of CLF in lateralized, small early T-stage OCC that un
derwent unilateral treatment (Table 4). In our cohort with favorable
prognosis and 5-year OS of 80.6%, the 5-year incidence of CLF was low
at 4.3%, providing support that omitting treatment to the contralateral
cN0 neck is a reasonable approach in well selected patients. For small
but deeply invasive tumors with DOI > 10 mm however, caution should
be applied with consideration of treating the bilateral neck
comprehensively.
Table 2
Patients with contralateral neck failure.
Patient
no.

Age

Primary
site

Pathological Tclassification*

DOI
(mm)

pN
status

LVSI

PNI

Adjuvant
RT

Local failure and
relation to CLF

Salvage surgery
for CLF?

Adjuvant RT post
salvage surgery

1
2

57
55

OT
OT

T1
T1

17
3

NA
Pos

Neg
Pos

Neg
Neg

No
No

Yes
Yes

Yes
Yes

3

62

OT

T1

NA

Pos

Neg

Neg

No

No

NA

4
5
6
7
8
9

60
51
44
58
58
61

FOM
OT
OT
OT
OT
OT

T2
T1
T2
T2
T2
T2

4
0.8
13
12
13
20

Neg
Neg
Pos
Neg
Pos
Neg

Neg
Neg
Neg
Pos
Neg
Neg

Neg
Neg
Pos
Pos
Neg
Neg

No
No
Yes
Yes
Yes
Yes

Yes, prior to CLF
Yes, synchronous
with CLF
Yes, synchronous
with CLF
No
Yes, prior to CLF
No
No
No
No

Yes
Yes
Yes
No
Yes
Yes

Yes
Yes
No
NA
Yes
Yes

*Pathological T-classification based on 7th edition AJCC; DOI = depth of invasion (measured in millimeters); pN status = pathological node status; LVSI = Lym
phovascular space invasion; PNI = perineural invasion; RT = radiotherapy; NA = not available; Pos = positive for pathological feature; Neg = negative for pathological
feature; CLF = contralateral neck failure.
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Fig. 1. Cumulative incidence of regional failure following unilateral treatment for lateralized, small oral cavity cancers.

events as first site of regional disease recurrence and ipsilateral node
positive status was significantly associated with CLF on UVA. This factor
did not remain statistically significant on MVA, which may relate to the
low number of CLF events. In comparison, a study of 243 patients with
OCC at high risk of contralateral nodal metastasis (predominantly
advanced T-stage OCC, with all lesions abutting or cross midline) found
29% had contralateral nodal metastasis, and ipsilateral node positive
status was the most significant factor associated with contralateral nodal
metastasis on MVA [1]. The DOI of the primary lesion however, was not
evaluated. As our cohort was predominantly node negative (81%), in the
setting of pathologically positive ipsilateral node/s, we would recom
mend discussion at a multidisciplinary tumor board when considering a
watchful waiting approach to the contralateral cN0 neck.
An interesting finding of this study was the significant association
between DOI > 10 mm and CLF on MVA in our cohort of small, later
alized OCC. These small tumors would now be upstaged to T3 disease on
the 8th edition AJCC staging [21], raising the question of whether these
tumors require the same comprehensive neck treatment as tumors that
meet the T3 criterion based on greatest surface dimension. Based on Tclassification alone, expert guidelines would suggest treating the bilat
eral neck comprehensively [2]. DOI in OCC has been shown to correlate
significantly with OS, disease specific survival and risk of nodal metas
tases [22–24]. However, the risk of contralateral nodal metastases have
not been addressed in OCC studies of DOI. Although prior studies of
lateralized OCC that included T3/T4 disease reported low rate of CLF in
the untreated contralateral neck [11,13,17], this subgroup accounted
for a minority of the study cohort. Staging systems prior to the incor
poration of DOI in the 8th edition AJCC staging were used in these
studies, and as extrinsic tongue muscle infiltration is no longer a crite
rion for T4 disease, it is possible that the reported T4 cohort could now
be downstaged based on DOI. A RCT would best guide standard of care
for the management of the contralateral cN0 neck in small but deeply
invasive lateralized tumors, however such a trial would be difficult to
initiate and accrue. Patients presenting with these tumors are uncom
mon and the management of the contralateral cN0 neck with END, RT or

Table 3
Clinico-pathological predictors for contralateral neck failure.
Univariate analysis

Multivariate analysis

Clinical factor

Hazard ratio
(95% CI)

pvalue

Hazard ratio
(95% CI)

pvalue

Tobacco/Betel Use
Yes vs. No
Alcohol Use
Yes vs. No
Pathological factor

3.4 (0.4–27.0)

0.26

3.1 (0.4–23.3)

0.26

Hazard ratio
(95% CI)

pvalue

Hazard ratio
(95% CI)

pvalue

pN + vs. pN0
pT2 vs. pT1
LVSI present vs.
absent
DOI ≥ 4 mm vs. < 4
mm
DOI > 10 mm vs. ≤
10 mm
PNI present vs.
absent
PD vs. WD/MD

9.5 (2.5–37.0)
3.0 (0.8–10.6)
4.0 (0.8–19.6)

<0.01
0.09
0.09

3.6 (0.7–16.9)

0.11

1.6 (0.3–8.1)

0.54

10.3 (2.5–41.7)

<0.01

6.7 (1.4–32.3)

0.02

1.5 (0.3–7.1)

0.61

0.8 (0.1–6.6)

0.81

pN+ = pathological neck node positive; pN0 = pathological neck node negative;
pT2 = pathological T2 classification (7th edition AJCC); pT1 = pathological T1
classification (7th edition AJCC); LVSI = lymphovascular space invasion; DOI =
depth of invasion; PNI = perineural invasion; PD = poorly differentiated; WD/
MD = well/moderately differentiated.

contralateral cN0 neck is performing risk stratification beyond charac
teristics of small and lateralized OCC in the absence of RCT data. We
assessed for potential clinico-pathological predictors associated with
CLF in our cohort, however similar to previous published series
(Table 4), CLF events were low and likely to impact the power to detect
associations. Ipsilateral nodal status has been reported as a predictor for
CLF in patients with lateralized OCC undergoing unilateral treatment,
although overall CLF events were low [11,13]. Our cohort had 9 CLF
4
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Fig. 2. Overall survival estimate following unilateral treatment for lateralized, small oral cavity cancers.

Fig. 3. Overall survival estimate by regional disease status.

END and postoperative RT to cover the surgically perturbed bed could
prove difficult to standardize and maintain study compliance. Thus, in
the absence of RCT data, a cautious approach in the management of a
small but deeply invasive OCC is recommended, with consideration of
treating the bilateral neck comprehensively. Future studies evaluating
outcomes of the untreated contralateral cN0 neck in small, lateralized
OCC should exclude deeply invasive lesions.
We acknowledge there are limitations to this study. Due to the
retrospective and multi-institutional nature of this study, we could not
reliably define the histopathological distance of the primary tumor from

midline and thus this was not recorded at the outset of developing this
multi-institutional database. Our inclusion and exclusion criteria
included those who best represented patients thought to have small
lateralized OCC at the time of treatment and were assessed to only
require unilateral treatment. Due to limited study numbers, we could
not compare outcomes of patients that had lateralized early T-stage
OCC, who received bilateral neck treatment with our current cohort.
However, as there was a low number of contralateral neck events seen in
the present study, such a comparison would unlikely yield additional
data on managing the contralateral cN0 neck. Nonetheless, this study
5
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Table 4
Literature review of failure rate in the node negative contralateral neck of oral cavity cancers.
Study

N

Primary
site

Pathological Tclassificationα

Lateralized
primary

Lateralized
treatment

N status

Adj Rx

Incidence of
contralateral neck
failure

Predictors of
contralateral neck
failure

MOCCC

176

OT (82%)
FOM
(18%)

T1 (68%)
T2 (32%)

Y

100% UNI

RT
(17%)

2 year incidence 3.6%
5 year incidence 4.3%
Crude rate 5%

DOI > 10 mm

Habib [11]

481

T1 (41%)
T2 (32%)
T3 (8%)
T4 (19%)

Y

100% UNI

RT
(34%)
CTX
(3%)

Crude rate 2.9%

pN+
Poor differentiation

Ganly [10]

164

OT (50%)
FOM
(17%)
ALV
(12%)
BUC
(10%)
RMT
(9%)
OT
(100%)

N+
(12%)
N0
(81%)
UNK
(7%)
N+
(33%)
N0
(67%)

T1 (46%)
T2 (54%)

NR

90% UNI
7% BL
3% NR

None

Crude rate 7%

NR

Nobis [7]

150

OT
(100%)

T1 (71%)
T2 (29%)

Y

70% UNI
30% BL

N+
(13%)β
N0
(87%)
N+
(23%)
N0
(77%)

Crude rate 2.7%

NR

Vergeer
[13]

104

T1 (24%)
T2 (30%)
T3 (10%)
T4 (36%)

No, 9% close/
cross midline

100% UNI

NR

5 year contralateral
neck control 92%

Number of positive
nodes

Waldram
[17]

101

T1 (11%)
T2 (40%)
T3 (9%)
T4 (40%)

NR

73% UNI
27% BL

N+
(72%)
N0
(28%)

RT
(75%)
CRT
(25%)

Crude rate 5%

NR

Wirtz [25]

74

OT (25%)
FOM
(8%)
ALV
(48%)
BUC
(19%)
OT (51%)
FOM
(17%)
ALV
(15%)
RMT
(10%)
BUC (7%)
NR

RT
(19%)
CRT
(6%)
CTX
(1%)
RT
(100%)

NR but includes T1T4

Y

NR

NR

NR

None

Lim [9]

54

OT
(100%)

T1 (19%)
T2 (81%)

Y

42% UNI
58% BL

RT
(34%)

O’steen
[12]

32

OT (72%)
FOM
(28%)

T1 (47%)
T2 (41%)
T3 (9%)
T4 (3%)

Y

66% UNI
22% BL
12% NR

N+
(28%)
N0
(72%)
N+
(19%)
N0
(81%)

5 year contralateral
neck control 93.5%
Crude rate 6.7%
Crude rate 0%

Crude rate 0%

NR

RT
(62%)
CRT
(38%)

NR

MOCCC = Multi-institutional Oral Cavity Collaborative group (present study). OT = oral tongue. FOM = floor of mouth. ALV = alveolus. BUC = buccal. RMT =
retromolar trigone. αPathological T-classification based on 7th edition AJCC. UNI = unilateral treatment. BL = bilateral treatment. N status = neck nodal status. Adj Rx
= adjuvant treatment. DOI = depth of invasion. pN+ = pathological node positive. NR = not reported. UNK = unknown. RT = radiotherapy. CRT = chemo
radiotherapy. CTX = chemotherapy. βmicrometastases detected of available lymph node dissection specimen (n = 52).

reports on the incidence of CLF in the largest cohort series to date of
small lateralized OCC receiving unilateral treatment and provides sup
port for omitting treatment to the contralateral cN0 neck in well selected
patients.
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